The FDA is initiating efforts to enhance clinical trial efficiency by real-time data review from AstraZeneca and Amgen trials, and soliciting public input on a pilot program leveraging AI for safety monitoring and patient recruitment. This move aims to accelerate drug development timelines, offering developers new tools to streamline their processes and potentially bring treatments to market faster. Watch for how the integration of AI in clinical trial management could set new standards in pharmaceutical research.
Read the full article at STAT Pharma
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

![[AINews] The Unreasonable Effectiveness of Closing the Loop](/_next/image?url=https%3A%2F%2Fmedia.nemati.ai%2Fmedia%2Fblog%2Fimages%2Farticles%2F600e22851bc7453b.webp&w=3840&q=75)



